179246-45-8

Basic information

• Product Name: 4-(2-fluorobenzyloxy)-3-chlorobenzenaMine
• Synonyms: 4-(2-fluorobenzyloxy)-3-chlorobenzenaMine;Lapatinib impurity E
• CAS NO: 179246-45-8
• Molecular Formula: C13H11ClFNO
• Molecular Weight: 251.6839432
• Mol File: 179246-45-8.mol

Chemical Properties

• Boiling Point: 390.5±32.0 °C(Predicted)
• Appearance: /
• Density: 1.306±0.06 g/cm3(Predicted)
• PKA: 3.95±0.10(Predicted)
• CAS DataBase Reference: 4-(2-fluorobenzyloxy)-3-chlorobenzenaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-fluorobenzyloxy)-3-chlorobenzenaMine(179246-45-8)
• EPA Substance Registry System: 4-(2-fluorobenzyloxy)-3-chlorobenzenaMine(179246-45-8)

Safety Data

• Hazardous Substances Data: 179246-45-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-fluorobenzyloxy)-3-chlorobenzenaMine is used as an antidepressant medication for the treatment of depression, as it helps to elevate mood and reduce depressive symptoms by increasing the availability of serotonin in the brain.
Used in Treatment of Mental Health Conditions:
In the mental health field, 4-(2-fluorobenzyloxy)-3-chlorobenzenaMine is used as a therapeutic agent for various conditions including obsessive-compulsive disorder, panic disorder, and bulimia nervosa, due to its modulating effects on serotonin levels which are implicated in these disorders.
Available in Multiple Forms:
4-(2-fluorobenzyloxy)-3-chlorobenzenaMine is utilized in different pharmaceutical forms such as capsules, tablets, and liquid, providing flexibility in administration to patients according to their needs and preferences.
Prescribed Under Brand Names:
This chemical is often prescribed under well-known brand names like Prozac and Sarafem, which are recognized for their use in treating depression and other related conditions.
Caution and Supervision Required:
It is important to use 4-(2-fluorobenzyloxy)-3-chlorobenzenaMine with caution and under medical supervision due to the potential for side effects and interactions with other medications, ensuring safe and effective treatment.

InChI:InChI=1S/C13H11ClFNO/c14-11-7-10(16)5-6-13(11)17-8-9-3-1-2-4-12(9)15/h1-7H,8,16H2

Upstream product

• 446-48-0 o-fluorobenzyl bromide 
• 619-08-9 2-chloro-4-nitrophenol 
• 179246-44-7 2-chloro-1-[(2-fluorobenzyl)oxy]-4-nitrobenzene 

Downstream Products

• 1393112-44-1 5-[4-({3-chloro-4-[(2-fluorobenzyl)oxy]phenyl}amino)quinazoline-6-yl]furan-2-carbaldehyde 
• 1393112-45-2 N-{3-chloro-4-[(2-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazoline-4-amine 

Relevant articles and documents

Methods for detecting and reducing impurities of Lapatinib and salts thereof

Impurities of lapatinib such as N-{3-chloro-4-[(2-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazoline-4-amine compound of formula (I) or a salt thereof: and analytical methods for identifying and quantifying such impurities of Lapatinib and salts thereof are provided. Also provided is Lapatinib containing less than about 0.05 percent of this and related impurities and methods for preparing such pure forms of Lapatinib.

PROTOZOAN PARASITE GROWTH INHIBITORS

Compounds and methods for inhibiting growth of a protozoan parasite. Methods of treating a protozoan parasite infection in a subject by administering a therapeutically effective amount of a compound as disclosed herein. The compounds and methods can be us

Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

A pharmaceutical formulation comprising the compound of formula

Kinase scaffold repurposing for neglected disease drug discovery: Discovery of an efficacious, lapatanib-derived lead compound for trypanosomiasis

Human African trypanosomiasis (HAT) is a neglected tropical disease caused by the protozoan parasite Trypanosoma brucei. Because drugs in use against HAT are toxic and require intravenous dosing, new drugs are needed. Initiating lead discovery campaigns b

CYANOQUINOLINE DERIVATIVES

Disclosed is a compound of formula I, a stereoisomer thereof, a cis-trans-isomer thereof, a tautomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof, wherein R1, R2, R3 and R4 are each as defined in the present application.

CYANOQUINOLINE DERIVATIVES

Disclosed is a compound of formula I, a stereoisomer thereof, a cis-trans-isomer thereof, a tautomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, a solvate thereof or a prodrug thereof, wherein R1, R2

Impurity of lapatinib and salts thereof

The present invention regards an impurity of lapatinib, N-{3-chloro-4-[(2-fluorobynzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl] quinazoline-4-amine compound of formula (I) or a salt thereof: the analytical methods for identifying it and quantifying it in Lapatinib and salts thereof. The invention also regards Lapatinib comprising less than 0.05 percent of this impurity and the relative method of preparation.